X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Roivant Sciences has secured $200 million to advance its protein degradation ambitions. Armed with the money, Roivant CEO Vivek Ramaswamy plans to use the VantAI platform to spawn multiple new biotech startups.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Roivant Sciences
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Investment December 06, 2020
Details:
More recently, the company has leveraged the power of its antibody discovery platform in select other areas of great unmet medical needs, such as in coronavirus disease (COVID-19).
Lead Product(s): HBM4003
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Nona Biosciences
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
